Table II.

Other infections in study participants

HRSN4224/42 (57%)25/42 (59%)33/39 (84%)22/42 (52%)19/42 (45%)
Pre-SC5416/53 (30%)34/53 (64%)36/46 (78%)29/54 (54%)20/54 (37%)
  • a Proportion of individuals who reported a syphilis/gonorrhea episode before the moment of sampling for activation marker measurement; of one pre-SC control no syphilis/gonorrhea record was available.

  • b Proportion of individuals who tested positive for HSV-1 or HSV-2 or HHV8. For three HRSN participants and 8 pre-SC controls, no data on HSV-1 status were available.